Your browser doesn't support javascript.
loading
Insights From Long-term Follow-up of a Girl With Adrenal Insufficiency and Sphingosine-1-Phosphate Lyase Deficiency.
Maharaj, Avinaash; Güran, Tülay; Buonocore, Federica; Achermann, John C; Metherell, Louise; Prasad, Rathi; Çetinkaya, Semra.
Afiliação
  • Maharaj A; Centre for Endocrinology, William Harvey Research Institute, John Vane Science Centre, Queen Mary, University of London, Charterhouse Square, London, United Kingdom.
  • Güran T; Marmara University, School of Medicine, Department of Paediatric Endocrinology and Diabetes, Istanbul, Turkey.
  • Buonocore F; Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Achermann JC; Genetics and Genomic Medicine Research and Teaching Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK.
  • Metherell L; Centre for Endocrinology, William Harvey Research Institute, John Vane Science Centre, Queen Mary, University of London, Charterhouse Square, London, United Kingdom.
  • Prasad R; Centre for Endocrinology, William Harvey Research Institute, John Vane Science Centre, Queen Mary, University of London, Charterhouse Square, London, United Kingdom.
  • Çetinkaya S; Health Sciences University, Dr. Sami Ulus Obstetrics and Gynecology, Children's Health and Disease Education and Research Hospital, Ankara, Turkey.
J Endocr Soc ; 6(5): bvac020, 2022 May 01.
Article em En | MEDLINE | ID: mdl-35308304
ABSTRACT

Introduction:

Sphingosine-1-phosphate lyase (SGPL1) insufficiency syndrome (SPLIS) is a multisystemic disorder which, in the main, incorporates steroid-resistant nephrotic syndrome and primary adrenal insufficiency (PAI). Case Presentation We present a young girl with a novel homozygous variant in SGPL1, p.D350G, with PAI in the absence of nephrotic syndrome. In the course of 15 years of follow-up she has further developed primary hypothyroidism and while she has progressed through puberty appropriately, ovarian calcifications were noted on imaging. The p.D350G variant results in reduced protein expression of SGPL1. We demonstrate that CRISPR engineered knockout of SGPL1 in human adrenocortical (H295R) cells abrogates cortisol production. Furthermore, while wild-type SGPL1 is able to rescue cortisol production in this in vitro model of adrenal disease, this is not observed with the p.D350G mutant.

Conclusion:

SGPL1 deficiency should be considered in the differential diagnosis of PAI with close attention paid to evolving disease on follow-up.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Endocr Soc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: J Endocr Soc Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido